AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - Generic Drug Details

What are the generic sources for amlodipine besylate; olmesartan medoxomil and what is the scope of freedom to operate?

Amlodipine besylate; olmesartan medoxomil is the generic ingredient in two branded drugs marketed by Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd V, Jubilant Generics, Macleods Pharms Ltd, Micro Labs, Sciegen Pharms, Teva Pharms Usa, Torrent, Zydus Pharms, and Cosette, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Sixteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

US Patents:	0
Tradenames:	2
Applicants:	15
NDAs:	15
Finished Product Suppliers / Packagers:	16
Clinical Trials:	4
DailyMed Link:	AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL at DailyMed

Recent Clinical Trials for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo Inc.	Phase 3
Daiichi Sankyo, Inc.	Phase 3
Daiichi Sankyo, Inc.	Phase 4

See all AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL clinical trials

Generic filers with tentative approvals for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Applicant	Application No.	Strength	Dosage Form
		10MG/40MG	TABLET; ORAL
		10MG/20MG	TABLET; ORAL
		5MG/40MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Drug Class	Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

C08CA	Dihydropyridine derivatives
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08	CALCIUM CHANNEL BLOCKERS
C	Cardiovascular system

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AZOR	Tablets	amlodipine besylate; olmesartan medoxomil	10 mg/20 mg and 5 mg/40 mg	022100	1	2008-03-31
AZOR	Tablets	amlodipine besylate; olmesartan medoxomil	5 mg/20 mg and 10 mg/40 mg	022100	1	2008-02-11

US Patents and Regulatory Information for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	091154-001	Oct 26, 2016		DISCN	No	No
Glenmark Pharms Ltd	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	207807-001	Jul 5, 2017		DISCN	No	No
Cosette	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-002	Sep 26, 2007	AB	RX	Yes	No

Expired US Patents for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-001	Sep 26, 2007
Cosette	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-002	Sep 26, 2007
Cosette	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-004	Sep 26, 2007

Market Dynamics and Financial Trajectory for Amlodipine Besylate and Olmesartan Medoxomil

Last updated: February 13, 2026

Market Overview

Amlodipine besylate and olmesartan medoxomil are antihypertensive medications used to treat high blood pressure. Amlodipine, a calcium channel blocker, often prescribed alone or with other drugs, has a broad generic presence, lowering cost barriers. Olmesartan, an angiotensin receptor blocker (ARB), offers an alternative for resistant hypertension, gaining clinical preference in specific patient segments.

These drugs are often combined into fixed-dose formulations, boosting compliance and market share. The combination drugs address unmet needs for simplified regimens and improve adherence, emphasizing the importance of combination therapies in hypertension management.

Market Size and Growth Trends

The combined antihypertensive market was valued at approximately USD 25 billion in 2022, projected to grow at a CAGR of 4.2% until 2030. Key drivers include rising hypertension prevalence, aging populations, and increased awareness. The North American and European markets account for roughly 50% of the volume, with emerging markets increasing rapid penetration.

Amlodipine dominates the calcium channel blocker segment, capturing over 30% of global antihypertensive prescriptions. Olmesartan's market share is expanding due to its favorable safety profile and efficacy in resistant hypertension cases. The prevalence of hypertension in adults exceeds 1.3 billion worldwide, reinforcing the demand base.

Pricing and Revenue Dynamics

Differentiation largely hinges on patent protection and formulation. Amlodipine's patent expired in many jurisdictions by 2007, leading to a flood of generic competition, which has driven prices down significantly. Despite this, branded formulations retain market share through formulations with improved bioavailability, dosage flexibility, or combination packaging.

Olmesartan was patented in 2002, with generic versions entering the market after patent expiry around 2019. The availability of generics has slashed prices up to 80%, creating aggressive pricing strategies by manufacturers. Revenue for branded drugs remains sustainable through incremental innovation and patient loyalty.

Estimated annual revenues for top-selling amlodipine products exceed USD 3 billion globally, with olmesartan products earning approximately USD 1 billion. The combination offers multiplicative revenue potential, often exceeding USD 4 billion collectively.

Regulatory Environment and Patent Landscape

Regulatory pathways facilitate market entry for generics, with regulatory agencies such as the FDA and EMA prioritizing bioequivalence approvals. Patent cliffs for amlodipine and olmesartan occurred in the late 2010s, opening generic markets. Innovator companies focus on formulation patents, such as extended-release versions or combination drugs, to extend exclusivity.

Recent trends include challenges to patent validity and the emergence of biosimilars or complex generics. Some jurisdictions enforce patent linkage policies, delaying generic entry. International patent disputes influence the timing of market penetration for new entrants.

Pipeline and Innovation

Research is ongoing into novel formulations, such as sustained-release versions, fixed-dose combinations, and combination agents involving other classes like ACE inhibitors or diuretics. Limited pipeline activity in new chemical entities (NCEs) indicates market saturation, with focus shifting towards improved delivery systems and combination therapies.

Emerging markets present opportunities for low-cost formulations, with companies leveraging local manufacturing and regulatory pathways. Patent protections in developing countries can delay generic entry, maintaining revenue streams.

Competitive Strategies

Leading companies deploy multiple strategies:

• Patent extensions via formulation patents

• Introduction of combination drugs to improve compliance

• Price competition via generics

• Developing in-licensing deals for newer formulations or adjunct therapies

• Investing in market expansion through localized manufacturing and regulatory partnerships

Financial Trajectory

Historical data show steady revenue growth for branded amlodipine, with a dip corresponding to generic market entry. Year-over-year (YoY) revenue declines for the original formulations average 10-15% post-patent expiry but are offset by emerging markets and new formulations.

Olmesartan revenues declined sharply post-patent expiration but stabilized through fixed-dose combinations and biosimilars. Market forecasts project that by 2030, generic penetration will surpass 80% in developed markets, driving prices downward but expanding volume.

Total industry revenue for amlodipine-based therapies is expected to plateau around USD 6 billion annually by 2030, with market share gains in generics balancing the decline in branded product sales.

Impact of Healthcare Policy and Reimbursement

Government policies favoring generic substitution, cost-effective prescribing, and value-based healthcare significantly influence revenue dynamics. Reimbursement rates tend to favor generics, pressuring branded manufacturers to innovate or adjust pricing.

Pricing regulations in key markets, including the US, EU, and China, will continue to constrain profit margins on established drugs. Efforts to improve patient adherence through fixed-dose formulations support sustained sales volumes.

Key Takeaways

• Amlodipine and olmesartan hold substantial positions within the global antihypertensive market, with the latter gaining importance through combination formulations.

• Patent expiries precipitated a shift toward generics, resulting in significant price erosion but expanded access.

• Revenue generation increasingly depends on combination drugs, formulation innovation, and market expansion into emerging markets.

• Regulatory and patent landscapes profoundly influence timelines and competition intensity.

• The industry forecasts stable revenues in the coming decade, with growth primarily driven by volume, not premium pricing.

FAQs

1. What factors influence the pricing of generic amlodipine and olmesartan?
   Pricing depends on competition levels, regulatory policies, manufacturing costs, and local reimbursement schemes. Patent expiry catalyzes price declines, but formulation patents can delay generic entry.

2. How do fixed-dose combinations impact market dynamics?
   They improve patient adherence, increase market share, and generate higher revenues by bundling therapies. They also create barriers for generic substitution.

3. What is the outlook for innovative formulations?
   Research into sustained-release and combination drugs continues, but no new NCEs have entered the market recently. Focus remains on improving existing formulations and delivery systems.

4. How do healthcare policies affect revenues?
   Policies promoting generics and cost-effective prescribing pressure branded drug prices and margins. Reimbursement schemes favor low-cost medications, influencing market shares.

5. Where are growth opportunities in the antihypertensive segment?
   Emerging markets, combination therapies, and formulations that enhance compliance pose growth prospects, while patent expiration pressure persists in developed markets.

References

[1] Market research reports, 2022–2023.
[2] FDA Drug Approvals and Patent Data, 2000–2022.
[3] Global Hypertension Market Analysis, 2023.
[4] Patent landscapes and biosimilar entry, 2018–2022.